Psychopharmacology for young children: clinical needs and research opportunities.
In response to concerns about the increasing use of psychotropic medications in preschoolers, the National Institute of Mental Health and the Food and Drug Administration convened a workshop in October 2000 to examine the current state of knowledge regarding psychopharmacology for young children and discuss a variety of topics relevant to research in this age group, including safety, efficacy, investigational methods, and ethical aspects. The meeting gathered researchers, practitioners, ethicists, industry staff, and family and patient representatives. Efficacy and safety of psychotropics have not been systematically evaluated in preschoolers. The major limitation to this research is the diagnostic uncertainty surrounding most manifestations of psychopathology in early childhood. Research in developmental psychopathology is needed to clarify diagnosis and provide sensitive and specific methods for clinical trials. Possible approaches to expanding the research basis of this area of clinical practice, including a recently started study of methylphenidate in preschoolers, are reported here.
Vitiello
B
B
Child and Adolescent Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, Bethesda, Maryland, USA. bvitiell@nih.gov
D000367:Age Factors; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D008774:Methylphenidate / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D012107:Research Design / Q000592:standards
D011619:Psychotropic Drugs; D008774:Methylphenidate